2013 ACC/AHA cholesterol treatment guidelines

Slides:

Advertisements

Similar presentations

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Advertisements

New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland.

On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs. 2004;9: LaRosa JC et al. N Engl J Med. 2005;352:

VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College.

Cholesterol Lowering and CV Risk: Meta-analyses. On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:

Baseline characteristics and eligibility criteria of participating trials Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2013 ACC/AHA Guideline on the Treatment of Blood.

Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Test in Context: High-Sensitivity C-Reactive Protein.

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Proposal to Incorporate Trial Data Into a Hybrid.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implications of Coronary Artery Calcium Testing.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Asymptomatic Individuals With a Positive Family.

NICE –CG 181 Continuum of CVD Risk and its treatment

Study of plasma fibrin D-Dimer as marker of fibrinolysis and high sensitive C-reactive protein (hs-CRP) as potential inflammatory marker in acute stage.

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

Major recommendation for statin therapy for ASCVD prevention

Predicted 5-year benefits of LDL cholesterol reductions with statin treatment at different levels of risk. (A) Major vascular events, and (B) vascular.

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

Phenotype vs. Genotype: Defining Severe Familial Hypercholesterolemia

Cholesterol practice questions

The accordion effect Journal of Indian College of Cardiology

Coronary spasm Journal of Indian College of Cardiology

First time a CETP inhibitor shows reduction of serious CV events

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

TNT: Baseline and final LDL cholesterol levels

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Use of the Coronary Artery Calcium Score in Discussion of Initiation of Statin Therapy in Primary Prevention Erin D. Michos, MD, MHS, Michael J. Blaha,

Neil J. Stone et al. JACC 2014;63:

Martin W. Schoen, MD, MPH, Joanne Salas, MPH, Jeffrey F

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Management of hypertension in patients with chronic kidney disease

Approach to the true resistant hypertensive and treatment approaches

Approach to the true resistant hypertensive and treatment approaches

Hypotension induced coronary spasm: A vascular access complication

Alan Gradman Journal of Indian College of Cardiology

Journal of Indian College of Cardiology

P. Foëx British Journal of Anaesthesia

Epidemiology of hypertension in India: Insights from PURE

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

Epidemiology of hypertension in India: Insights from PURE

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Eric Peterson Journal of Indian College of Cardiology

Review of treatment for varicose veins

Glycemic control for macrovascular disease in type II diabetes: Evidence and insights from recent trials Sanjay Rajagopalan Journal of Indian College.

Hypertension management in high risk type II diabetes with CKD: Insights from recent trials with a focus on albuminuria. A case based discussion Matthew.

Journal of Indian College of Cardiology

If triglycerides matter, why do they matter?

2013 ACC/AHA cholesterol treatment guidelines

The Potential Effects of Implementing the 2013 ACC/AHA Cholesterol Guidelines on the Use of Statins in a Large Health Maintenance Organization in Israel

Contemporary Evidence-Based Guidelines

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Khurram Nasir et al. JACC 2015;66:

Potential mechanisms whereby statins may reduce the risk of stroke

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study Heart Protection.

Goals & Guidelines A summary of international guidelines for CHD

Cause of death Treatment-arm events, % (n=45 054)

Jon S. Matsumura, MD, Adnan Z. Rizvi, MD Journal of Vascular Surgery

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease Dean G. Karalis, MD Mayo Clinic Proceedings

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

III. Treating dyslipidemias

Presentation transcript:

2013 ACC/AHA cholesterol treatment guidelines Sanjay Rajagopalan Journal of Indian College of Cardiology Volume 5, Pages S15-S20 (March 2015) DOI: 10.1016/j.jicc.2015.03.008 Copyright © 2015 Terms and Conditions

Fig. 1 Effects on major coronary events, strokes, coronary revascularization procedures, and major vascular events per 1·0 mmol/L reduction in LDL cholesterol at different levels of risk. MVE = major vascular event. RR = rate ratio. CI = confidence interval. Source: Cholesterol Treatment Trialists′ (CTT) Collaborators. Lancet. 2012 Aug 11; 380(9841): 581–590 Journal of Indian College of Cardiology 2015 5, S15-S20DOI: (10.1016/j.jicc.2015.03.008) Copyright © 2015 Terms and Conditions

Fig. 2 Major recommendations for statin therapy for ASCVD prevention. Journal of Indian College of Cardiology 2015 5, S15-S20DOI: (10.1016/j.jicc.2015.03.008) Copyright © 2015 Terms and Conditions

Fig. 3 Primary prevention in those without diabetes/ASCVD and LDL-C 70–189 mg/dl. *FHX-Family History, CRP-C reactive protein, CAC-coronary artery calcium scores, TLC-Therapeutic lifestyle changes. Journal of Indian College of Cardiology 2015 5, S15-S20DOI: (10.1016/j.jicc.2015.03.008) Copyright © 2015 Terms and Conditions

Fig. 4 Percent of U.S. adults who would be eligible for statin therapy for primary prevention, according to set of guidelines and age group. Source: Michael J. Pencina et al. N Engl J Med 2014;370:1422-31 Journal of Indian College of Cardiology 2015 5, S15-S20DOI: (10.1016/j.jicc.2015.03.008) Copyright © 2015 Terms and Conditions

Fig. 5 Improved risk stratification with coronary calcium scoring. Source: Madhavan MV, et al. J Am Coll Cardiol. 2014 May 6;63(17):1703-14 Journal of Indian College of Cardiology 2015 5, S15-S20DOI: (10.1016/j.jicc.2015.03.008) Copyright © 2015 Terms and Conditions